Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jwa-Kyung | - |
dc.contributor.author | Kwon, Young Joo | - |
dc.contributor.author | Kim, Soo Wan | - |
dc.contributor.author | Kim, Yeong-Hoon | - |
dc.contributor.author | Park, Cheol Whee | - |
dc.contributor.author | Choi, Kyu Bok | - |
dc.contributor.author | Hwang, Seung Duk | - |
dc.contributor.author | Choi, Kyu Hun | - |
dc.date.accessioned | 2021-09-06T03:41:33Z | - |
dc.date.available | 2021-09-06T03:41:33Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-03-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103763 | - |
dc.description.abstract | Purpose: Cinacalcet is effective for treating refractory secondary hyperparathyroidism (SHPT), but little is known about the response rates and clinical factors influencing the response. Materials and Methods: A prospective, single-arm, multi-center study was performed for 24 weeks. Cinacalcet was administered to patients with intact parathyroid hormone (iPTH) level greater than 300 pg/mL. Cinacalcet was started at a dose of 25 mg daily and titrated until 100 mg to achieve a serum iPTH level <300 pg/mL (primary end point). Early response to cinacalcet was defined as a decrease of iPTH more than 50% within one month. Results: Fifty-seven patients were examined. Based on the magnitude of iPTH decrease, patients were divided into responder (n=47, 82.5%) and non-responder (n=10, 17.5%) groups. Among the responders, 38 achieved the primary end point, whereas 9 patients showed a reduction in serum iPTH of 30% or more, but did not reach the primary end point. Compared to non-responders, responders were significantly older (p=0.026), female (p=0.041), and diabetics (p<0.001). Additionally, early response was observed more frequently in the responders (30/47, 63.8%), of whom the majority (27/30, 90.0%) achieved the primary end point. Multivariate analysis showed that lower baseline iPTH levels [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.93-0.99], the presence of diabetes (OR 46.45, CI 1.92-1125.6) and early response (OR 21.54, CI 2.94-157.7) were significant clinical factors affecting achievement of iPTH target. Conclusion: Cinacalcet was effective in most hemodialysis patients with refractory SHPT. The presence of an early response was closely associated with the achievement of target levels of iPTH. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | YONSEI UNIV COLL MEDICINE | - |
dc.subject | SECONDARY HYPERPARATHYROIDISM | - |
dc.subject | CALCIMIMETIC AGENT | - |
dc.subject | BONE METABOLISM | - |
dc.subject | SERUM-CALCIUM | - |
dc.subject | DIALYSIS | - |
dc.subject | DISEASE | - |
dc.subject | OUTCOMES | - |
dc.subject | HCL | - |
dc.subject | PTH | - |
dc.title | Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kwon, Young Joo | - |
dc.identifier.doi | 10.3349/ymj.2013.54.2.453 | - |
dc.identifier.scopusid | 2-s2.0-84873272867 | - |
dc.identifier.wosid | 000315540600026 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.54, no.2, pp.453 - 463 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.citation.title | YONSEI MEDICAL JOURNAL | - |
dc.citation.volume | 54 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 453 | - |
dc.citation.endPage | 463 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001745374 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | SECONDARY HYPERPARATHYROIDISM | - |
dc.subject.keywordPlus | CALCIMIMETIC AGENT | - |
dc.subject.keywordPlus | BONE METABOLISM | - |
dc.subject.keywordPlus | SERUM-CALCIUM | - |
dc.subject.keywordPlus | DIALYSIS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | HCL | - |
dc.subject.keywordPlus | PTH | - |
dc.subject.keywordAuthor | Cinacalcet | - |
dc.subject.keywordAuthor | end-stage renal disease | - |
dc.subject.keywordAuthor | hemodialysis | - |
dc.subject.keywordAuthor | parathyroid hormone | - |
dc.subject.keywordAuthor | secondary hyperparathyroidism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.